Small therapeutic molecules for the treatment of inflammatory bowel disease.
New therapies for inflammatory bowel disease are needed, because standard therapies fail to induce remission in about 30% of patients, and because of the relative inefficacy of current maintenance therapies. This review summarises the current status of the development of small therapeutic molecules for inflammatory bowel disease.
van Deventer
S J H
SJ
Department of Hepato-Gastroenterology, Academic Medical Center, Amsterdam, the Netherlands.
D051722:ADAM Proteins; D000072198:ADAM17 Protein; D003424:Crohn Disease / Q000188:drug therapy; D015777:Eicosanoids / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D009569:Nitric Oxide / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000378:metabolism; D011498:Protein Precursors; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013792:Thalidomide / Q000627:therapeutic use; D014157:Transcription Factors / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D015777:Eicosanoids; D010726:Phosphodiesterase Inhibitors; D011498:Protein Precursors; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D013792:Thalidomide; C061153:tumor necrosis factor precursor; D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000072198:ADAM17 Protein